Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2026)

Kiniksa Pharmaceuticals International has reported EBT Margin for 6 years, with the latest figure at 15.25% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin rose 396.0% year-over-year to 15.25%; the trailing twelve-month figure through Mar 2026 stood at 14.06% (up 1377.0% YoY), and the FY2025 full-year result was 13.12%, up 1984.0% from the prior year.
• EBT Margin for Q1 2026 stood at 15.25%, up from 11.51% in the prior quarter.
• The five-year high for EBT Margin was 59.51% in Q4 2022, with the low at 86.37% in Q4 2023.
• Historically, EBT Margin has averaged 7.02% across 5 years, with a median of 1.73% in 2023.
• Annual changes were most pronounced in 2022 — EBT Margin soared 45491 bps — and 2023, when it sank 14588 bps.
• Kiniksa Pharmaceuticals International's EBT Margin stood at 59.51% in 2022, then slumped by 245 bps to 86.37% in 2023, then soared by 91 bps to 7.59% in 2024, then soared by 252 bps to 11.51% in 2025, then surged by 32 bps to 15.25% in 2026.
• The last three EBT Margin figures came in at 15.25% (Q1 2026), 11.51% (Q4 2025), and 15.02% (Q3 2025), per Business Quant data.